History

  • January, 2011

    Silence announces its progress in developing proprietary delivery technologies for siRNA therapeutics (AtuPLEX®, DACC and DBTC).

  • August, 2010

    Silence’s partner Quark signs exclusive option agreement with Novartis for development and commercialisation QPI-1002 (AtuRNAi) in two kidney indications. Silence receives US$1m and potential milestone payments of up to US$82m.

  • January, 2010

    Silence acquired US RNAi therapeutics company Intradigm Corp. and thereby strengthened its intellectual property position in RNAi therapeutics (‘Zamore Design Rules’ patent estate licensed from the University of Massachusetts) and simultaneously raised GBP15m funding from Intradigm’s vc investors and institutional investors.

  • August, 2009

    Silence signs delivery collaboration with Dainippon Sumitomo.

  • November, 2008

    Silence’s core RNAi (AtuRNAi) patent was granted in the US.

  • March, 2008

    AstraZeneca and Silence sign delivery collaboration.

  • July, 2007

    AstraZeneca and Silence sign siRNA research collaboration and license agreement for 5 targets and Silence receives US15m in upfront and equity and potential milestone payments of up to US$400m. Silence’s market cap amounts to GBP175m (US$350m).

  • January, 2007

    Silence’s core RNAi (AtuRNAi) patent was granted in Europe.

  • October, 2006

    Announcement that Nobel Prize in Medicine was granted to Andrew Fire and Craig Mello, the inventors of RNA interference.

  • September, 2006

    Pfizer in-licensed the first AtuRNAi preclinical program from Silence’s collaboration partner Quark Pharma - Silence receives US$3.5m and potential milestone payments of up to US$95m.Silence’s market cap amounts to GBP13m (US$ 26m).

  • February, 2005

    Reverse merger with SR Pharma plc (shell) listed on AIM, London followed by a fund raising of GBP10m mainly from institutional UK investors

  • February, 2002

    First core RNAi (AtuRNAi) patent application filed in Germany.

  • January, 2000

    Further funding by Apax (€10m) and MPM Capital (€5m).

  • January, 1999

    1999: Silence Therapeutics AG, Berlin (formerly Atugen AG) was founded as spin-off from Ribozyme Pharmaceuticals Inc. (later renamed to Sirna Therapeutics Inc.) funded by MPM Capital (US$7m). The company’s core business focused on target discovery and validation collaborations with leading pharma companies using its proprietary antisense and delivery technologies.